GlassScriptPhysician profile
Jesalyn D Wilson
NPI 1205226925
$1,778.29
in general payments reported to CMS, 2019-2025
21 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $316 · 2022: $441 · 2023: $319 · 2024: $543 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $476.81 | 2021-2025 | |
| Glaxosmithkline, LLC. | $221.54 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $157.58 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $128.29 | 2022-2025 | Farxiga, Airsupra |
| Pfizer INC. | $104.19 | 2021-2023 | |
| Novo Nordisk INC | $100.56 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $95.17 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.65 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $85.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.74 | 2021-2024 | Jardiance |
| Abbott Laboratories | $37.20 | 2021-2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $35.19 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $28.95 | 2021 | |
| Mylan Specialty L.P. | $25.84 | 2023-2024 | Yupelri |
| Procept Biorobotics Corporation | $23.29 | 2024 | Aquabeam System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.15 | 2023 | Aptima |
| Biohaven Pharmaceuticals, INC. | $15.41 | 2021 | |
| Currax Pharmaceuticals LLC | $15.04 | 2023 | Contrave, Onzetra Xsail |
| Genentech USA, INC. | $14.09 | 2022 | |
| Boston Scientific Corporation | $11.46 | 2021 | |
| Redhill Biopharma INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesalyn Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.